STAMPEDE事后分析:治疗中PSA与前列腺癌总生存的关系
该研究基于STAMPEDE平台五项3期随机试验的7129例患者数据,采用landmark分析评估随机化后6、12、24周PSA与总生存的关联。
要点
- 转移体积或淋巴结状态影响PSA亚组的96个月总生存率,包括PSA不可测者。
- PSA联合影像特征可更好预测生存,并值得在临床试验中评估用于治疗选择。
核心结论
- 转移体积或淋巴结状态影响治疗中PSA分类对应的生存率,包括PSA不可测的情况。
- 影像学特征与血清PSA可联合用于更好地预测生存。
研究设计与样本
- STAMPEDE平台五项3期随机对照试验的事后分析,纳入2005年10月5日至2016年9月2日招募的7129例患者。
- 4438例转移性、2691例极高危非转移性前列腺腺癌,来自瑞士和英国126家医院或肿瘤中心。
- 采用landmark分析检验随机化后6、12、24周PSA与总生存的关联,各分析仅纳入有PSA值的患者。
- 用Kaplan-Meier法估计按转移体积或淋巴结状态分层的96个月总生存率及95%CI。
临床怎么用
- 解读PSA结果时应结合转移体积或淋巴结状态,避免单一PSA阈值误判预后。
- PSA联合影像特征可能改善生存预测,但用于治疗选择仍需临床试验评估。
局限性
- 为事后分析,仅纳入各landmark分析时有PSA值的患者。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Serum prostate-specific antigen (PSA) concentrations decrease after hormone therapy for prostate cancer, with the nadir serving as a potentially useful prognostic biomarker. To support clinical use, we evaluated the association between PSA nadir values and survival outcomes, stratified by pre-treatment metastatic volume or, in patients with non-metastatic cancer, stratified by lymph node status. METHODS: As part of the STAMPEDE platform trial, patients with metastatic or very high-risk non-metastatic prostate adenocarcinoma were recruited to five randomised, controlled, phase 3 trials conducted at 126 hospitals or oncology centres in Switzerland and the UK. Patients were randomly assigned to either standard of care (androgren deprivation therapy [ADT] alone or ADT plus docetaxel) or to one of five experimental treatment groups: ADT plus docetaxel with or without zoledronic acid, ADT plus abiraterone acetate with or without enzalutamide, or ADT plus prostate radiotherapy (only patients with metastatic disease). We used trial data from these participants to perform landmark analyses to test associations of PSA at 6, 12, and 24 weeks after randomisation with overall survival. Only patients with a PSA value were included in each landmark analysis. The Kaplan-Meier method was used to estimate 96-month overall survival rates and the corresponding 95% CIs for patients categorised by either metastatic volume or lymph node status. The STAMPEDE protocol platform is registered with ClinicalTrials.gov (NCT00268476), EUDRACT (2004-000193-31), and ISRCTN (ISRCTN78818544). FINDINGS: This study included 7129 patients from the STAMPEDE platform, who were recruited between Oct 5, 2005, and Sept 2, 2016; 4438 had metastases and 2691 had very high-risk non-metastatic disease. Among patients with metastasis and volumetric assessment, 2211 (55·9%) of 3956 had high-volume metastases, and among those with non-metastatic disease, 1033 (38·4%) were lymph node positive. A PSA concentration of 0·2 ng/mL or less was less frequent at 6 weeks or 12 weeks, but was associated with equivalent survival rates, compared with a PSA of 0·2 ng/mL or less at 24 weeks. Survival rates of PSA subcategories (≤0·2 ng/mL, >0·2 to 1·0 ng/mL, >1·0 to 3·0 ng/mL, and >3·0 ng/mL) differed by metastatic volume or, in patients with non-metastatic disease, by nodal status. Survival was longest for patients allocated to abiraterone with or without enzalutamide. Among patients with metastatic disease in the abiraterone with or without enzalutamide group who had a PSA of 0·2 ng/mL or less at 24 weeks, 96-month overall survival in patients with low-volume metastatic disease (64·1% [95% CI 57·8-69·8]) was higher than in patients with high-volume metastatic disease (44·6% [37·1-51·9]), but lower than in patients with non-metastatic, node-positive disease (79·4% [73·8-83·9]). 96-month overall survival was highest for patients with non-metastatic, node-negative disease (82·8% [95% CI 78·7-86·1]). INTERPRETATION: Metastatic volume or nodal status influence survival rates associated with on-treatment serum PSA categories, including for undetectable PSA. Radiological features and serum PSA could be combined to better predict survival. PSA at 24 weeks showed strongest associations with overall survival, although a PSA concentration of 0·2 ng/mL or less at any timepoint predicted favourable outcome. These findings could inform prognosis and warrant evaluation for treatment selection in clinical trials. FUNDING: Cancer Research UK, Prostate Cancer UK, UK Medical Research Council, and John Black Charitable Foundation.
引用
- Kayani M, Murphy L, Dutey-Magni P, et al. On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trials. Lancet Oncol. 2026. PMID: 42061373. doi:10.1016/S1470-2045(26)00066-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。